CytoDyn's chief scientific officer Rahman quietly exits amid leronlimab limbo Bannister joins SVB to help companies raise cash, access public markets Ventus raises $100M to pursue NLRP3, crack undruggable targets Sponsored: NAFLD & NASH: Emerging In Vitro Models Aid Drug Discovery Mission Bio, poised for growth, snags Thermo Fisher veteran Zhang as new CEO ValenzaBio picks up $70M, Pierre Fabre antibody for inflammatory eye disease FDA grants first COVID-19 antibody green light for at-home, fingerprick blood test Lilly, AbCellera tout COVID-19 antibody combo potential as it loses strength against variants AstraZeneca COVID-19 shot tagged with new warning in EU, highlighting rare blood clot risk Featured Story | By Ben Adams CytoDyn has lost its chief scientific officer Mahboob Rahman, M.D., Ph.D., just six months into his tenure at the biotech. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor SVB Leerink has hired Jack Bannister from Goldman Sachs. In the new role, Bannister will “partner with healthcare and life sciences companies to raise capital and position them for success in the public markets.” read more By Nick Paul Taylor Ventus Therapeutics has raised a $100 million series B to take small molecules against traditionally undruggable targets into clinical trials. The pipeline features NLRP3 inhibitors that Ventus is pitching as best-in-class candidates in the competitive inflammasome space. read more Sponsored By: BioIVT Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common pathologies without specialized therapeutics, but new models may provide opportunities for drug discovery. read more By Amirah Al Idrus After a decade at Thermo Fisher Scientific, Yan Zhang is taking the helm of Mission Bio from Charlie Silver. Silver, the company’s co-founder and CEO who led the team that developed the company’s platform and took it to market, will move into an advisory role. read more By Amirah Al Idrus Maryland’s ValenzaBio reeled in a $70 million series A round that will propel a pair of monoclonal antibody programs toward the clinic. Those include a treatment for an autoimmune kidney disease, which is poised to start a phase 1b/2a study in the second quarter of this year, and a treatment for thyroid eye disease (TED) licensed from Pierre Fabre Medicament. read more By Andrea Park Antibody testing just went DIY: The FDA has given the go-ahead to a COVID-19 test that can detect the virus’s antibodies in a dried blood spot sample taken at home. read more By Angus Liu The feds stopped distributing Eli Lilly's and AbCellera's COVID drug bamlanivimab as a monotherapy, out of concern that it may not be effective against new coronavirus variants. Now the companies have new findings that they believe provide support for the drug to be used with another antibody to protect against those variants. read more By Fraiser Kansteiner Unusual blood clots with low blood platelets should be listed as a “very rare” side effect of AstraZeneca's COVID-19 vaccine, the European Medicines Agency said Wednesday. With cases piling up over the past month, several countries have stopped using the shot altogether. read more Resources Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: PerkinElmer Informatics Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes. Sponsored By: OCT Clinical Find out why more than 400 clinical trials annually are initiated in Russia by US and EU pharma in the free annual report by OCT Clinical. Sponsored by: PulsePoint Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Almac Clinical Technologies This industry report reveals qualitative and quantitative candid insight from clinical development insiders and their views on current clinical trial challenges faced amidst uncertainty. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Learn what it takes to get a drug developed and approved April 13-14, 2021 | 12 p.m. EST / 9 a.m. PST
Pharma PR & Communications Virtual Summit April 20–22, 2021 | Virtual Event Learn the science driving biopharma. Specific for the non-scientist. April 20-21, 2021 | 12 p.m. EST / 9:00 a.m. PST Medical Affairs Strategic Summit (MASS) Virtual May 5-7, 2021 | Virtual Event TMF Virtual Summit May 18-20, 2021 | Virtual Event Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST | 